

ActivBiotics

[View the current ActivBiotics Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/17831-ActivBiotics.html)

(<http://www.bioportfolio.com/biocorporate/17831-ActivBiotics.html>)

Contact Details:

**110 Hartwell Ave
Lexington
Massachusetts
02421
United States of America**

Tel: 781-372-4800
Fax: 781-274-9129
Email: info@activbiotics.com

ActivBiotics, Inc. is a private biopharmaceutical company focused on the discovery, development and commercialization of breakthrough therapies for the treatment of vascular disease, inflammation and infectious diseases. The Company's lead product, rifalazil, is currently being developed as a novel therapy for peripheral arterial disease (PAD), including intermittent claudication (leg pain), a serious complication of atherosclerosis. In addition to rifalazil, ActivBiotics is advancing a pipeline of proprietary drug candidates representing large markets that can be studied in relatively small clinical trials. ActivBiotics is developing compounds that mimic the function of superoxide dismutase (SOD) thereby removing superoxide, a toxic free radical implicated in a number of conditions associated with tissue injury and inflammatory diseases. M40403 is a clinical stage SOD mimetic being developed for post-operative ileus, oral mucositis and other inflammatory conditions. The Company is also developing rifamycin-based antibiotics for the treatment of serious bacterial infections

Recent Publications by ActivBiotics:



- [Rifalazil retains activity against rifampin-resistant mutants of *Chlamydia pneumoniae*.](#)
Rifampin-resistant mutants of the obligate intracellular pathogen... 20th December, 2008
ActivBiotics, - J Antibiot (Tokyo). 2008 Aug;61(8):489-95. ([DOI Direct Link](#))
- [Rifalazil and derivative compounds show potent efficacy in a mouse model of *H. pylori* colonization.](#)
The rifamycin rifalazil (RFZ), and derivatives (NCEs) were efficacious in... 20th December, 2008
ActivBiotics, Inc., - J Antibiot (Tokyo). 2008 Aug;61(8):485-8. ([DOI Direct Link](#))
- [Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters.](#)
PURPOSE: M40403 is a small-molecule superoxide dismutase mimetic that has... 1st August, 2008
ActivBiotics, Inc., Lexington, Massachusetts, USA.- Clin Cancer Res. 2008 Jul 1;14(13):4292-7. ([DOI](#))

[Direct Link](#))

- [Determination of rifalazil in dog plasma by liquid-liquid extraction and LC-MS/MS: quality assessment by incurred sample analysis.](#)
Incurred dog plasma samples were utilized for method quality assessment in... 4th March, 2008
ActivBiotics, Inc., 110 Hartwell Avenue, Lexington, MA 02421, USA.- J Pharm Biomed Anal. 2007 Nov 30;45(4):616-24. Epub 2007 Sep 12. ([DOI Direct Link](#))
- [Rifalazil and other benzoxazinorifamycins in the treatment of chlamydia-based persistent infections.](#)
Rifalazil is a benzoxazinorifamycin which inhibits bacterial DNA-dependent... 6th February, 2008
ActivBiotics, Inc., Lexington, Massachusetts 02421, USA.- Arch Pharm (Weinheim). 2007 Oct;340(10):517-29. ([DOI Direct Link](#))
- [Determination of rifalazil, a potent antibacterial agent, in human plasma by liquid-liquid extraction and LC-MS/MS.](#)
A sensitive assay for determination of rifalazil (also known as ABI-1648... 31st January, 2008
ActivBiotics, Inc., 110 Hartwell Avenue, Lexington, MA, USA.- J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Nov 1;859(1):103-10. ([DOI Direct Link](#))
- [In vitro activity of novel rifamycins against gram-positive clinical isolates.](#)
We describe novel rifamycins that have improved activity, compared with... 4th January, 2008
ActivBiotics, Inc., - J Antibiot (Tokyo). 2007 Sep;60(9):572-6. ([DOI Direct Link](#))
- [Lack of effect of rifalazil on ethinyl estradiol pharmacokinetics in healthy postmenopausal women.](#)
Rifalazil, a second-generation rifamycin, is being evaluated for the... 6th December, 2007
ActivBiotics, - Int J Clin Pharmacol Ther. 2007 Jul;45(7):418-22.
- [Development potential of rifalazil and other benzoxazinorifamycins.](#)
Rifalazil and other benzoxazinorifamycins (new chemical entities [NCEs])... 30th October, 2007
ActivBiotics, Inc., 110 Hartwell Avenue, Lexington, MA 02421, USA.- Expert Opin Investig Drugs. 2006 Jun;15(6):603-23. ([DOI Direct Link](#))
- [Effect of food on the pharmacokinetics of rifalazil, a novel antibacterial, in healthy male volunteers.](#)
Rifalazil is a new antibiotic structurally related to rifampin but devoid... 21st August, 2007
ActivBiotics, - J Clin Pharmacol. 2007 Jul;47(7):841-9. Epub 2007 Apr 26. ([DOI Direct Link](#))
- [Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection.](#)
Novel rifamycins (new chemical entities [NCEs]) having MICs of 0.002 to... 12th December, 2006
ActivBiotics, Inc., 110 Hartwell Ave., Lexington, MA 02421, USA.- Antimicrob Agents Chemother. 2006 Nov;50(11):3658-64. Epub 2006 Aug 28. ([DOI Direct Link](#))
- [Enhanced activity of rifalazil in combination with levofloxacin, linezolid, or mupirocin against Staphylococcus aureus in vitro.](#)
Rifalazil is a potent second-generation ansamycin that kills bacterial... 31st August, 2006
ActivBiotics Inc., 110 Hartwell Ave., Lexington, MA 02421, USA.- J Antibiot (Tokyo). 2006 May;59(5):303-8. ([DOI Direct Link](#))
- [In vitro time-kill activities of rifalazil, alone and in combination with vancomycin, against logarithmic and stationary cultures of Staphylococcus aureus.](#)
Rifalazil is a novel rifamycin that, like other members of this class,... 23rd May, 2006
ActivBiotics Inc., 128 Spring St., Lexington, MA 02421, USA.- J Antibiot (Tokyo). 2006 Feb;59(2):80-5. ([DOI Direct Link](#))
- [In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.](#)
We describe novel rifamycin derivatives (new chemical entities [NCEs])... 28th April, 2006
ActivBiotics, Inc., 110 Hartwell Avenue, Lexington, Massachusetts 02421, - Antimicrob Agents Chemother. 2006 Mar;50(3):827-34. ([DOI Direct Link](#))
- [A series of heterocyclic inhibitors of phenylalanyl-tRNA synthetases with antibacterial activity.](#)
A series of novel heterocyclic analogues have been synthesized and... 13th October, 2004
Department of Medicinal Chemistry, Cubist Pharmaceuticals Inc., 24 Emily- Bioorg Med Chem Lett. 2004 Mar 8;14(5):1343-6. ([DOI Direct Link](#))

Press Releases on ActivBiotics:

<p>Joseph F. Finn, Jr., Assignee for the Benefit of Creditors of EPIX Pharmaceuticals, Inc., Releases Statement Regarding Liquidation Process</p>	<p>22nd October, 2009</p>	<p>Joseph F. Finn, Jr., C.P.A.</p>	<p>WELLESLEY HILLS, Mass., Oct. 22 /PRNewswire/ -- The previously announced auction of assets of EPIX Pharmaceuticals, Inc. was conducted on October 21, 2009. As of today, claims filed against the</p>
<p>Epix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009</p>	<p>1st October, 2009</p>	<p>Joseph F. Finn, Jr., C.P.A.</p>	<p>WELLESLEY HILLS, Mass., Oct. 1 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that there was a successful auction sale of five drug program intellectual properties on</p>
<p>EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction</p>	<p>1st September, 2009</p>	<p>Joseph F. Finn, Jr., C.P.A.</p>	<p>WELLESLEY HILLS, Mass., Sept. 1 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the P2Y2 Gastrointestinal Early Development Candidate Program will be part of the</p>
<p>EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction</p>	<p>25th August, 2009</p>		<p>WELLESLEY HILLS, Massachusetts, August 25 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the PRX-00023 Therapeutics Program in Phase 2b/3 will be part of the</p>
<p>Prospect Therapeutics Inc.'s GCS-100 Has Focused on Developing Treatment for Three Blood-Borne Cancers</p>	<p>22nd June, 2009</p>	<p>Joseph F. Finn, Jr., C.P.A.</p>	<p>WELLESLEY HILLS, Mass., June 22 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") announced today that Prospect Therapeutics has focused on developing GCS-100 for treatment of three</p>

ActivBiotics Clinical Trials:



- [PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients](#)



ActivBiotics Patents:

- 7547692- [Rifamycin analogs and uses thereof](#)
- 7494991- [Rifamycin analogs and uses thereof](#)
- 7488726- [Rifamycin analogs and uses thereof](#)
- 7342011- [Rifamycin analogs and uses thereof](#)
- 7271165- [Rifamycin analogs and uses thereof](#)
- 7220738- [Rifamycin analogs and uses thereof](#)
- 7122525- [Targeted therapeutics and uses thereof](#)
- 7078399- [Sulfhydryl rifamycins and uses thereof](#)
- 6900204- [Antimicrobial agents and uses thereof](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

